Qualified researchers studying endocrine signalling and growth-hormone-releasing pathways are increasingly working with the CJC-1295 peptide as a laboratory tool. At PeptideValidation.com, we supply research-grade CJC-1295 as a 5 mg lyophilized powder for controlled laboratory studies. This article breaks down the peptide's molecular identity, how its DAC variant differs, what current literature records about observed effects and cjc-1295 side effects in model systems, and what rigorous quality standards look like for any CJC-1295 compound entering your lab.

What Is the CJC-1295 Peptide?

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) consisting of 30 amino acids. It binds GHRH receptors in the anterior pituitary to stimulate growth-hormone secretion. The DAC (Drug Affinity Complex) variant extends plasma half-life from roughly 30 minutes to 6-8 days by covalently bonding to circulating albumin.

CJC-1295 was first described in the early 2000s as a modified GHRH fragment. The native GHRH peptide is cleaved rapidly by dipeptidylpeptidase IV (DPP-IV), limiting its research utility in longer-duration studies. CJC-1295 addresses this by substituting four amino acids that confer DPP-IV resistance.

The most studied form is CJC-1295 with DAC. DAC stands for Drug Affinity Complex, a maleimidoproprionic acid (MPA) group attached to lysine at position 28. This group reacts with the free cysteine-34 residue on serum albumin, creating a covalent bond that dramatically extends the peptide's half-life in research models.

Without DAC, the molecule (sometimes called Modified GRF 1-29) has a half-life of 30 minutes or less. The DAC version extends that to an estimated 6-8 days, which has made it useful for studies requiring prolonged GHRH receptor stimulation. Researchers should clearly distinguish which variant they are working with, because cjc-1295 with dac dosage protocols and study timelines differ substantially from those used for the DAC-free form.

From a structural standpoint, the peptide is supplied as a lyophilized white powder. PeptideValidation.com provides it in 5 mg units, a common quantity for multi-experiment laboratory programs. Proper reconstitution with bacteriostatic water and cold-chain storage at -20 degrees C are standard requirements for maintaining structural integrity before use.

How CJC-1295 Interacts With Growth-Hormone-Releasing Pathways

CJC-1295 binds to GHRH receptors on pituitary somatotroph cells, triggering intracellular cAMP signalling that stimulates growth-hormone gene transcription and secretion. In animal models, single doses have raised plasma GH levels 2-10x above baseline, with IGF-1 elevations persisting for several days when the DAC form is used.

The anterior pituitary contains somatotroph cells that express GHRH receptors on their surface. When CJC-1295 occupies these receptors, it activates adenylyl cyclase, raises intracellular cyclic AMP (cAMP), and triggers a downstream signalling cascade that promotes both GH synthesis and pulsatile GH release.

In preclinical rodent studies published between 2004 and 2020, researchers documented GH elevations ranging from 2x to 10x baseline following single-dose administration. These elevations were dose-dependent and showed a characteristic pulsatile pattern, suggesting the peptide amplifies natural GH secretion rhythms rather than overriding them entirely.

IGF-1 (insulin-like growth factor-1), produced primarily in the liver in response to GH, also rose in these models. With the cjc-1295 dac peptide variant, IGF-1 elevations persisted for 72-96 hours post-injection in some rodent studies. This extended IGF-1 response is a key reason researchers use the DAC form when studying downstream metabolic or anabolic signalling over multi-day intervals.

It is worth noting that GH secretion is also regulated by somatostatin, the inhibitory counterpart to GHRH. Some researchers combine CJC-1295 with ghrelin mimetics (GHRPs) in their protocols to reduce somatostatin tone simultaneously, producing synergistic GH responses. Designing such a study requires careful attention to timing, dosing intervals, and endpoint selection. For a broader view of the research landscape, see our complete guide to the CJC-1295 peptide.

CJC-1295 With DAC vs. Without DAC: Key Research Differences

The two main research forms differ in half-life, dosing frequency, and study design requirements. CJC-1295 without DAC (Modified GRF 1-29) peaks quickly and clears within hours, suiting acute-pulse studies. CJC-1295 with DAC sustains elevated GH and IGF-1 for days, making it better suited for chronic-exposure or pharmacokinetic studies.

Choosing between the DAC and non-DAC forms is one of the first decisions researchers face when designing a CJC-1295 study. The choice shapes nearly every procedural variable.

CJC-1295 without DAC (Modified GRF 1-29)

• Half-life: approximately 30 minutes
• GH peak: sharp, within 15-30 minutes of administration in rodent models
• Suitable for: acute GH-pulse studies, circadian GH rhythm research, short-duration protocols
• Dosing frequency: multiple times per day in animal studies

CJC-1295 with DAC

• Half-life: approximately 6-8 days (albumin-bound)
• GH peak: broader, sustained elevation over 1-4 days in animal models
• Suitable for: pharmacokinetic studies, chronic-exposure models, IGF-1 trajectory research
• cjc-1295 with dac dosage in published rat studies: typically 2-4 micrograms per kilogram, once or twice weekly

One practical point: because the DAC form circulates for nearly a week, any unexpected biological response in the animal model will also persist longer. Researchers designing safety-observation windows should factor this into their protocols.

Purity and identity verification matter here too. A DAC-bearing peptide that has undergone even partial hydrolysis at the maleimide linkage loses its albumin-binding capacity and begins to behave more like the non-DAC form. This is one reason mass spectrometry confirmation of intact molecular weight is essential before any study begins.

What Laboratory Studies Record About CJC-1295 Effects and Safety Signals

Published animal studies note increased GH and IGF-1 levels, changes in body composition (lean mass gain, fat reduction), and altered glucose metabolism as the most consistent observed effects. Recorded cjc-1295 side effects in animal models include transient injection-site reactions, water retention markers, and mild hypoglycaemia at higher doses.

Laboratory research on cjc-1295 peptide benefits and safety signals comes primarily from rodent and non-human primate models. Human pharmacokinetic data does exist from a 2006 clinical pharmacology study in healthy adults (Teichman et al., Journal of Clinical Endocrinology and Metabolism), though that research was exploratory in nature.

In the Teichman study, single-dose CJC-1295 with DAC produced mean GH increases of 2 to 10-fold over 6 days, and mean IGF-1 increases of 1.5 to 3-fold that were sustained for 9-11 days. No serious adverse events were reported at the doses tested, though the study was not powered to detect rare events.

In animal models, documented cjc-1295 side effects cluster into three categories:

1. Local reactions at the injection site in subcutaneous-administration models, typically self-resolving within 24-48 hours.
2. Fluid retention markers, consistent with GH's known anti-natriuretic effects.
3. Glucose metabolism changes, including transient reductions in fasting glucose at high doses, which have been linked to GH's insulin-opposing effects at the receptor level.

Researchers should note that cjc-1295 peptide benefits observed in animal models (improved body composition, enhanced tissue repair signalling) cannot be extrapolated to humans without formal clinical trial evidence. This compound is intended exclusively for laboratory research purposes and is not approved for therapeutic use.

For accurate interpretation of these signals in your own studies, correlating GH and IGF-1 assay results with batch-specific COA data is essential. Impure or partially degraded peptide will produce attenuated or erratic responses that compromise reproducibility.

Quality Standards That Matter for CJC-1295 Research Compounds

A research-grade CJC-1295 compound should meet these five quality criteria: (1) purity above 98% confirmed by HPLC, (2) molecular weight verified by mass spectrometry, (3) batch-specific COA with visible test dates, (4) sterility or bioburden data for injectable-use studies, and (5) documented cold-chain storage from manufacture to delivery.

The integrity of any CJC-1295 study depends heavily on compound quality. Peptides degrade through hydrolysis, oxidation, and aggregation. Without verified purity data, you cannot distinguish a biological null result from a bad-batch artefact.

PeptideValidation.com evaluates vendors against objective quality criteria, and researchers sourcing CJC-1295 should ask for the same documentation regardless of where they buy. Here is what to check:

HPLC purity should be stated as a percentage with the method described (reverse-phase C18 column is standard). For research-grade CJC-1295, 98% purity or above is the accepted threshold. Any COA reporting only a single UV-absorption peak without retention-time data should raise a question.

Mass spectrometry (MS) confirms molecular identity. The expected molecular weight of CJC-1295 with DAC is approximately 3647 Da. If the MS trace is absent from the COA or shows a significant offset, the batch should not enter your study.

Batch and lot numbers allow you to trace results back to a specific manufacturing run. Studies using multiple batches should document each lot separately to account for inter-batch variability.

Storage and shipping conditions matter as much as manufacturing quality. CJC-1295 in lyophilized form is stable at -20 degrees C for 24 months when stored dry. Exposure to ambient humidity or freeze-thaw cycles degrades the structure. Verify that vendors ship on dry ice and provide temperature-monitoring documentation.

PeptideValidation.com's 5 mg lyophilized CJC-1295 is supplied with batch-specific COAs that include HPLC and MS data, supporting the kind of reproducible endocrine and metabolic research that qualified laboratories require.

Common Researcher Questions: CJC-1295 Peptide Dosage and Study Design

Published animal studies typically use CJC-1295 with DAC at 2-4 micrograms per kilogram of body weight, administered once or twice weekly. CJC-1295 without DAC (Modified GRF 1-29) is used at 1-2 micrograms per kilogram, multiple times daily. These are research model figures only and do not constitute dosing guidance for any other use.

One of the most searched topics in this space is cjc-1295 peptide dosage, and for good reason. Getting the dosing range wrong in animal studies produces either sub-threshold responses (wasted peptides and time) or supraphysiological stimulation that makes results hard to interpret.

Published rodent studies give us a reasonable reference frame. The Teichman 2006 human PK study used single-dose equivalents ranging from 30 micrograms to 120 micrograms per kilogram in the human cohort. Scaled back to a typical 25 g mouse, that corresponds to roughly 0.75 to 3 micrograms per animal per session.

For chronic studies using the DAC form, many published protocols settle on twice-weekly dosing to maintain relatively stable plasma levels without excessive accumulation. For acute GH-pulse studies with the non-DAC form, multiple daily injections are standard.

Study design considerations beyond dosage include:

• Endpoint timing: GH peaks within 30 minutes for non-DAC; plan blood draws accordingly. IGF-1 peaks 24-72 hours post-dose for the DAC variant.
• Control groups: saline-injected controls are minimum; a native GHRH control arm strengthens your interpretation.
• Species selection: rat pituitary GHRH receptor expression patterns differ from mouse; review the species-specific literature before finalising your model.
• Combination protocols: if combining CJC-1295 with a GHRP such as GHRP-6 or ipamorelin, timing the two injections within 5-10 minutes of each other is standard practice based on published synergy data.

For a complete breakdown of how CJC-1295 fits into the broader research peptide landscape, the full CJC-1295 research guide on PeptideValidation.com covers synthesis, mechanism, and vendor-qualification criteria in depth.

Is CJC-1295 a Steroid? Clearing Up the Classification

CJC-1295 is not a steroid. It is a synthetic peptide, meaning it is a chain of amino acids, not a lipid-derived molecule. Steroids are built on a four-ring carbon backbone derived from cholesterol. CJC-1295 works through a completely different receptor class (GHRH receptors) and has no androgenic, estrogenic, or glucocorticoid activity.

The question 'is cjc-1295 a steroid' appears regularly in researcher forums, and it is worth answering clearly.

Steroids are a class of lipid molecules defined by a cyclopentanoperhydrophenanthrene ring structure. Testosterone, cortisol, and estradiol are steroids. They act primarily through intracellular nuclear receptors to alter gene transcription over hours to days.

CJC-1295 is a peptide: a string of 30 amino acids held together by peptide bonds. It acts on a cell-surface G-protein-coupled receptor (the GHRH receptor), triggering cAMP signalling over a timescale of minutes. There is no structural, pharmacological, or mechanistic overlap with steroidal compounds.

This distinction matters practically. Peptides and steroids require different storage conditions, different analytical testing methods, and fall under different regulatory frameworks in research settings. A COA for a peptide will report purity by HPLC and identity by MS. A steroid panel on that same COA would be irrelevant and should not be interpreted as a quality indicator for CJC-1295.

It also matters for study design. Unlike anabolic steroids, CJC-1295 does not bind androgen receptors. Body-composition changes observed in animal models attributed to CJC-1295 operate through the GH/IGF-1 axis, not through androgen-driven anabolic pathways. Distinguishing these mechanisms is critical for accurate reporting and for designing the right control conditions in your experiment.

Frequently asked questions